PDS Biotech: NCI-led Phase 2 study of PDS01ADC shows median PFS 9.6 months in mCRPC

PDS Biotechnology Corp

Median PFS of 9.6 months (range 4.3-32.2) for PDS01ADC plus docetaxel in 3rd-line mCRPC patients.
Median PSA decline of 40%; 6 of 16 patients achieved >50% PSA decline.
Data presented at AACR special conference on prostate cancer (Boston, Jan 20-22, 2026).
Study by NCI/NIH evaluating PDS01ADC synergy with docetaxel in advanced prostate cancer.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.